Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628142 | 0.96 | HCRTR1 (0.35) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628140 | 0.95 | HCRTR1 (0.35) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628143 | 0.90 | MAPK8 (0.35) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13627961 | 0.88 | MAPK8 (0.40) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628191 | 0.88 | NPC1 (0.39) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628220 | 0.87 | MAPK8 (0.37) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628244 | 0.87 | NPC1 (0.38) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628280 | 0.87 | HCRTR1 (0.38) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628138 | 0.87 | HCRTR1 (0.36) | NPC1RAB9APOLBNPSR1KDM4E | |
| SCHEMBL13628252 | 0.86 | POLB (0.40) | NPC1RAB9APOLBNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1175399-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) | VERTEX PHARMA (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | NPC1 1715/4885RAB9A 3486/4885POLB 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.